MAPT and Alzheimer disease: There is a wealth of evidence suggesting that CSF and neuroimaging biomarkers may be already altered in SCD [4–6]; Aβ42 and tau, two well-established biomarkers in AD continuum, have been shown to be significantly different in SCD compared to controls [4] and are able to discriminate individuals with SCD who will decline over time from those who will not [5].